Medical device company Avita is investing NT$300–350 million to establish a manufacturing facility in Thailand, aiming to sidestep the ongoing U.S.-China trade conflicts. Construction is expected to be completed by the third quarter of next year, with mass production slated for 2026. To support the funding needs of the new facility, Avita’s board has approved a capital increase of up to 6 million shares, targeting NT$190 million in raised funds.
Avita’s three flagship products include forehead thermometers, blood pressure monitors, and nasal aspirators. During the pandemic, the thermometer industry accumulated significant inventory. After nearly two years of clearing excess stock, brand customers are resuming orders, boosting Avita’s monthly revenue growth since June. As of October, the company’s cumulative revenue reached NT$778 million, narrowing the year-over-year decline to just 0.39%. Avita also reported an EPS of NT$1.02 for the first three quarters.
Thanks to a resurgence of orders from major Japanese clients and steady deliveries from smaller contracts, analysts expect Avita’s fourth-quarter performance to improve compared to the same period last year. Annual revenue is anticipated to return to growth. Looking ahead to next year, new product launches by clients and orders from new customers are expected to further enhance operations, painting an even more optimistic outlook.
With Donald J. Trump now projected as the next U.S. president, his policies include reinstating a 10% tariff hike on Chinese goods entering the U.S. To mitigate the effects of these tariffs, Avita’s new factory in Thailand broke ground in October. This strategic move aims to bolster the company’s competitiveness and reduce customer tariff burdens. The facility is projected to begin mass production by the second quarter of 2026.
Resource: 豪展砸逾3億 赴泰設廠
